TY - JOUR
T1 - Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients
AU - Høgdall, Estrid
AU - Fung, Eric T
AU - Christensen, Ib Jarle
AU - Yip, Christine
AU - Nedergaard, Lotte
AU - Engelholm, Svend Aage
AU - Risum, Signe
AU - Petri, Anette Lykke
AU - Lundvall, Lene
AU - Lomas, Lee
AU - Høgdall, Claus
N1 - Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
PY - 2010/12/1
Y1 - 2010/12/1
N2 - Purpose: To determine if the level of apolipoprotein A1, hepcidin, transferrin, inter-α trypsin IV internal fragment, transthyretin (TT), connective-tissue activating protein 3 (CTAP3), serum amyloid A1, β-2 microglobulin (B2M) might have impact on overall and progression-free survival for ovarian cancer (OC) patients.Experimental design: Serum from 150 OC patients was tested using SELDI-TOF-MS.Results: A proteomic prognostic index (xb-pro) was constructed using the regression coefficients based on inter-α trypsin IV internal fragment, B2M and TT. A multivariable Cox survival analysis including the xb-pro index showed that xb-pro (p<0.0001, HR=2.50, 95% CI: 1.65-3.79), residual tumor after primary surgery (p=0.0005), age (p=0.01) and chemotherapy (p=0.0002) are of independent prognostic value for overall survival. International Federation of Gynecology and Obstetrics stage, performance status, histological type of tumor and serum CA125 were found of no independent value. A proteomic index (xb-pfs) based on B2M and CTAP3 was found to predict progression-free survival (xb-pfs: p=0.008, HR=1.77, 95% CI: 1.17-2.70 together with type of surgery, age and chemotherapy.Conclusions and clinical relevance: We found an index with three proteomic biomarkers (xb-pro) to be of independent prognostic value for overall survival and an index with two proteomic biomarkers (xb-pfs) with evidence of independent prognostic value for progression-free survival.
AB - Purpose: To determine if the level of apolipoprotein A1, hepcidin, transferrin, inter-α trypsin IV internal fragment, transthyretin (TT), connective-tissue activating protein 3 (CTAP3), serum amyloid A1, β-2 microglobulin (B2M) might have impact on overall and progression-free survival for ovarian cancer (OC) patients.Experimental design: Serum from 150 OC patients was tested using SELDI-TOF-MS.Results: A proteomic prognostic index (xb-pro) was constructed using the regression coefficients based on inter-α trypsin IV internal fragment, B2M and TT. A multivariable Cox survival analysis including the xb-pro index showed that xb-pro (p<0.0001, HR=2.50, 95% CI: 1.65-3.79), residual tumor after primary surgery (p=0.0005), age (p=0.01) and chemotherapy (p=0.0002) are of independent prognostic value for overall survival. International Federation of Gynecology and Obstetrics stage, performance status, histological type of tumor and serum CA125 were found of no independent value. A proteomic index (xb-pfs) based on B2M and CTAP3 was found to predict progression-free survival (xb-pfs: p=0.008, HR=1.77, 95% CI: 1.17-2.70 together with type of surgery, age and chemotherapy.Conclusions and clinical relevance: We found an index with three proteomic biomarkers (xb-pro) to be of independent prognostic value for overall survival and an index with two proteomic biomarkers (xb-pfs) with evidence of independent prognostic value for progression-free survival.
U2 - 10.1002/prca.200900171
DO - 10.1002/prca.200900171
M3 - Journal article
SN - 1862-8346
VL - 4
SP - 940
EP - 952
JO - Proteomics - Clinical Applications
JF - Proteomics - Clinical Applications
IS - 12
ER -
